Cytosorbents (CTSO) Cost of Revenue (2011 - 2026)

Cytosorbents (CTSO) has reported Cost of Revenue for 16 consecutive years, with $2.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue fell 7.81% year-over-year to $2.6 million; the trailing twelve-month figure through Jun 2026 stood at $10.6 million (down 8.72% YoY), and the FY2025 full-year result was $10.6 million, down 1.27% from the prior year.
• Cost of Revenue fell to $2.6 million in Q2 2026 per CTSO's latest filing, from $2.7 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $4.5 million in Q3 2022 and bottomed at $2.1 million in Q2 2023.
• Historically, Cost of Revenue has averaged $2.8 million across 5 years, with a median of $2.6 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue jumped 82.46% in 2022, then slumped 51.91% in 2023.
• Over 5 years, Cost of Revenue stood at $3.6 million in 2022, then sank by 35.42% to $2.3 million in 2023, then advanced by 23.42% to $2.9 million in 2024, then slipped by 16.09% to $2.4 million in 2025, then gained by 6.34% to $2.6 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $2.6 million, $2.7 million, and $2.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.